• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by enVVeno Medical Corporation

    11/14/24 4:50:32 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care
    Get the next $NVNO alert in real time by email
    SC 13G/A 1 d912091dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

     

    enVVeno Medical Corporation

    (Name of Issuer)

    Common Stock, $0.00001 par value per share

    (Title of Class of Securities)

    29415J 106

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 29415J 106

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Advisors LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,869,219

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,869,219

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,869,219

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IA


    CUSIP No. 29415J 106

     

     1   

     NAMES OF REPORTING PERSONS

     

     Joseph Edelman

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,869,219

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,869,219

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,869,219

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN


    CUSIP No. 29415J 106

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Life Sciences Master Fund, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,869,219

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,869,219

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,869,219

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     CO


    Item 1(a).

    Name of Issuer:

    enVVeno Medical Corporation (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    70 Doppler, Irvine, California 92618

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.00001 par value per share (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    29415J 106

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 17,536,000 outstanding shares of Common Stock, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 31, 2024, giving effect to the exercise of an aggregate of 1,174,904 warrants and/or pre-funded warrants held by the Master Fund that can currently be exercised.


    Neither Perceptive Advisors nor Mr. Edelman directly holds any Common Stock. The Master Fund directly holds (i) 694,315 shares of Common Stock, (ii) 1,759,035 pre-funded warrants to purchase shares of Common Stock at an exercise price of $0.001 per share, (iii) 861,192 pre-funded warrants to purchase shares of Common Stock at an exercise price of $0.0001 per share, (iv) 861,192 warrants to purchase shares of Common Stock at $8.334 per share, and (v) 861,192 warrants to purchase shares of Common Stock at $6.945 per share. The warrants and pre-funded warrants may not be exercised if the Reporting Persons would beneficially own more than 9.9% of the Issuer’s outstanding shares of Common Stock after giving effect to such exercise. Accordingly, the Master Fund could exercise an aggregate of 1,174,904 warrants and/or pre-funded warrants currently. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: November 14, 2024

    PERCEPTIVE ADVISORS LLC

     

    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title:  Managing Member

     

    /s/ Joseph Edelman

    JOSEPH EDELMAN

    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

     

    By:   Perceptive Advisors LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title:  Managing Member
    Get the next $NVNO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVNO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVNO
    Leadership Updates

    Live Leadership Updates

    See more
    • enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

      Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve®PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024IRVINE, CA / ACCESSWIRE / April 9, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Andrew Cormack has been hired as the Company's Chief Commercial Officer. Mr. Cormack, who joined enVVeno Medical on April 8, comes to enVVeno following a career at both start-up and large medical device companies including WallabyPhenox, Medtronic, Covidien,

      4/9/24 8:45:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

      IRVINE, CA / ACCESSWIRE / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at Medtronic.Mr. Belteau joined Medtronic as a field engineer upon graduation from college and has progressed through various clinical operations roles over the course of his tenure there. Most recently he managed his own team of clinical operations professionals and has been directly involved is more than 75 clinical st

      8/16/22 8:05:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    Financials

    Live finance-specific insights

    See more
    • enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

      85% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97% Target Vein Patency RateImprovement in All Patient Reported Quality-of-Life IndicatorsCompany to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st A

      11/20/24 8:30:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

      Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH SymposiumCompany to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 19, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell the VenoValve in the United States. Four (4) out of five (5) modules that comprise the VenoValve PMA application

      11/19/24 8:15:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical to Host Conference Call and Webcast on September 21, 2022

      - Conference call with live audio webcast to be held on Wednesday, September 21st at 4:30 PM ETIRVINE, CA / ACCESSWIRE / September 19, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it will host a conference call and webcast on Wednesday, September 21, 2022 at 4:30 PM ET.Interested participants and investors may access the conference call by dialing (877) 407-9708 (domestic) or (201) 689-8259 (international) and referencing conference ID: 13732870. The live webcast will be accessible on the Events page of the Investors section of the enVVeno website, envveno.com, and w

      9/19/22 8:05:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    SEC Filings

    See more
    • enVVeno Medical Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - enVVeno Medical Corp (0001661053) (Filer)

      5/20/25 4:30:22 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by enVVeno Medical Corporation

      10-Q - enVVeno Medical Corp (0001661053) (Filer)

      4/30/25 5:28:15 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

      8-K - enVVeno Medical Corp (0001661053) (Filer)

      4/21/25 4:05:32 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Bright Jennifer

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      5/20/25 4:40:04 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Bright Jennifer

      3 - enVVeno Medical Corp (0001661053) (Issuer)

      5/20/25 4:35:31 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • Director Duhay Francis bought $249,999 worth of shares (81,433 units at $3.07), increasing direct ownership by 389% to 102,344 units (SEC Form 4)

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      1/3/25 7:00:20 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by enVVeno Medical Corporation

      SC 13G/A - enVVeno Medical Corp (0001661053) (Subject)

      11/14/24 4:50:32 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by enVVeno Medical Corporation (Amendment)

      SC 13G/A - enVVeno Medical Corp (0001661053) (Subject)

      2/23/24 4:16:05 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by enVVeno Medical Corporation

      SC 13G - enVVeno Medical Corp (0001661053) (Subject)

      2/14/24 4:51:40 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

      Successful Completion of All Planned Implants in GLP StudyenVVe Delivery System Demonstrates Consistent PerformanceCompany Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The successful completion of all planned implants in the GLP study, including both long-t

      12/16/24 8:50:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

      Interviews with participating patients from the VenoValve® U.S. Pivotal TrialWebcast replay from with the presenting Primary InvestigatorsPresentation with data from the VenoValve U.S. Pivotal TrialAccess the Recap Website Here!IRVINE, CA / ACCESSWIRE / November 27, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch of a recap website which highlights the Company's participation at the recently held 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium. Materials accessible on the recap website include interviews with two patients and

      11/27/24 8:30:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

      85% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97% Target Vein Patency RateImprovement in All Patient Reported Quality-of-Life IndicatorsCompany to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st A

      11/20/24 8:30:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Duhay Francis bought $249,999 worth of shares (81,433 units at $3.07), increasing direct ownership by 389% to 102,344 units (SEC Form 4)

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      1/3/25 7:00:20 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • Director Gray Robert bought $10,290 worth of shares (3,500 units at $2.94), increasing direct ownership by 46% to 11,155 units (SEC Form 4)

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      1/2/25 4:05:22 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • Director Shrivastava Sanjay bought $15,660 worth of shares (5,400 units at $2.90), increasing direct ownership by 139% to 9,288 units (SEC Form 4)

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      12/26/24 4:30:21 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care